Phathom Pharmaceuticals Stock Forum

$Phathom Pharmaceuticals(PHAT.US)$ In a report released today,  from Needham maintained a Buy rating on Phathom Pharmaceuticals ( – ), with a price target of $26.00.
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...

$Phathom Pharmaceuticals(PHAT.US)$ FDA Approves VOQUEZNA® for Relief of Heartburn
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏

$Phathom Pharmaceuticals(PHAT.US)$ this is your good chance to ride the bus

$Phathom Pharmaceuticals(PHAT.US)$ Phathom Pharmaceuticals Announces FDA Approval of Voquezna® (Vonoprazan) Tablets for the Relief of Heartburn Associated With Non-Erosive Gerd in Adults

Don't miss out! 🎯👇
$Phathom Pharmaceuticals(PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA: 7/19/24 (NDA)
$AstraZeneca(AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom:  7/25/24(sBLA)
$BeiGene(BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas
‣ PDUFA: July 2024 (BLA)

1 PDUFA this week! 🔥
$Arcutis Biotherapeutics(ARQT.US)$ : pending decision 🤔
⇨ ARQ-151 topical roflumilast cream
‣ Atopic Dermatitis (aged 6 & older children)
‣ PDUFA date: 7/7/24 (sNDA)
Upcoming PDUFAs & AdCom in July: 📅👇
$Phathom Pharmaceuticals(PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA date: 7/19/24 (NDA)
$AstraZeneca(AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom date:  7/25/24(sBLA)
$BeiGene(BGNE.US)$ :...

🔥 July: 3 PDUFAs & 1 AdCom
$Arcutis Biotherapeutics(ARQT.US)$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals(PHAT.US)$ : VOQUEZNA® (vonoprazan)
$AstraZeneca(AZN.US)$ : Imfinzi + chemotherapy - AdCom
$BeiGene(BGNE.US)$ : TEVIMBRA (tislelizumab)

$Phathom Pharmaceuticals(PHAT.US)$ NEWS
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
SynOx Therapeutics has closed a $75m Series B financing round led by Forbion, HealthCap, and Bioqube Ventures to fund a Phase 3 trial of emactuzumab, a potential best-in-class treatment for Tenosynovial Giant Cell Tumour (TGCT). Emactuzumab has shown promising clinical activity with a 71% objective response rate and good tolerability in earl...